Lower Drug Prices: Studying Intermediaries and Competition in Pharma Market
This act aims to investigate how companies that act as intermediaries in drug delivery, such as pharmacy benefit managers, operate. The goal is to determine if their actions are increasing drug prices or limiting competition. The study's findings will help create new rules to ensure lower drug prices and greater transparency for patients.
Key points
The government will investigate if drug intermediaries (e.g., PBMs) are overcharging for prescription drugs.
It will be examined whether these companies steer patients to their own pharmacies or misuse pharmacy data for their benefit.
The goal is to increase transparency and competition in the drug market, aiming for lower prices for citizens.
New regulations will be proposed to prevent unfair practices and ensure that savings from company mergers benefit consumers.
Expired
Citizen Poll